Objective To investigate the efficacy of thalidomide combined with afatinib in the treatment of advanced lung cancer.Methods A total of 65 patients with advanced lung cancer were studied and divided into group A(33 cases,including 1 case of intolerance)and group B(32 cases,including 2 cases of intolerance,accidental death)by random numerical table.Group A was treated with afatinib,group B was treated with thalidomide and afatinib.Both groups were compared in terms of median survival time,incidence of complications,efficacy[objective response rate(ORR),disease control rate(DCR)],and the levels of tumor markers[carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),cytokeratin fragment 19(CYFRA21-1)]before and after treatment.Results 3 cases were lost to follow-up until April 2023,with a follow-up rate of 95.38%(62/65).The median survival time of group B(12.3 months)was longer than that of group A(11.9 months).The incidence of complications of 3.33%in group B was lower than that of 25.00%in group A,and the difference was statistically significant(P<0.05).ORR of 76.67%and DCR of 90.00%in group B were higher than those of 50.00%and 68.75%in group A,and the differences were statistically significant(P<0.05).In group A,the levels of CEA,VEGF and CYFRA21-1 after treatment were(80.39±15.38)μg/L,(70.58±15.49)pg/ml and(3.55±1.48)μg/L.In group B,the levels of CEA,VEGF and CYFRA21-1 after treatment were(78.49±15.30)μg/L,(68.49±15.35)pg/ml and(3.49±1.53)μg/L.After treatment,the levels of CEA,VEGF and CYFRA21-1 in both groups were lower than those before treatment in this group,and the differences were statistically significant(P<0.05).However,there was no statistically significant difference between groups after treatment(P>0.05).Conclusion Thalidomide combined with afatinib is an effective method for the treatment of patients with advanced lung cancer,which can reduce the incidence of complications,prolong the median survival time,and is well tolerated by patients.

目的:探究培美曲塞联合铂类药治疗晚期或复发转移性肺癌的临床效果.方法:选取于我院治疗的晚期或复发性转移性肺癌患者120例作为本次研究对象,采用数字随机法分为对照组和联合组,分别采取培美曲塞及培美曲塞联合铂类药治疗,经治疗后对比两组病患的临床治疗效果.结果:经治疗可知对照组、联合组两组病患的疾病控制率对比有差异显著(P＜0.05),而相较于对照组,联合组痛患的不良反应发生率较高,但对比差异无统计学意义(P＞0.05).结论:采用培美曲塞联合铂类药治疗晚期或复发转移性肺癌,疾病控制效果较好.

目的:观察鸦胆子油注射液联合TP方案化疗治疗晚期肺癌的有效性及安全性.方法:选择3-4期晚期肺癌86例,随机分为治疗组45例,对照组41例.治疗组给予鸦胆子油注射液联合TP方案化疗,对照组给予TP方案化疗.疗程结束后,比较两组近期疗效,生存质量及不良反应.结果:两组近期有效率差异P＜0.05,治疗组有效率53.3%,优于对照组有效率34.1%,治疗组生活质量评分提高64.4%,优于对照组提高46.3%,不良反应发生率低于对照组.结论:鸦胆子油注射液联合TP方案化疗治疗晚期肺癌疗效显著.

目的:观察ELF方案治疗晚期胃肠道肿瘤的近期疗效和毒副反应.方法:40例晚期胃肠道肿瘤病人用ELF方案治疗:依托泊苷(Vp-16)100mg静脉点滴,第1～3d;醛氢叶酸(CF)100～300mg静脉点滴,第1～3d;氟脲嘧啶(5-Fu)750～1000mg静脉点滴,第1～3d;28d为1疗程.结果:总缓解率为52.5%(21/40),完全缓解率(CR)为5%(2/40),部分缓解率(PR)为47.5%(19/40).主要毒副反应为骨髓抑制和胃肠道反应,多为Ⅰ～Ⅱ级.其它毒副反应少见.结论:ELF方案治疗晚期胃肠道肿瘤的疗效肯定,毒副反应可以耐受,价格低廉.

目的:观察羟基喜树碱(HCPT)与氟尿嘧啶(5-Fu)联合化疗晚期胃肠道肿瘤的疗效.方法:48例晚期胃肠道肿瘤病人用HCPT与5-Fu联合化疗:连用5d,21d为1周期.结果:28例胃癌,CR 2例,PR 12例,总缓解率为50%;大肠癌20例,CR 3例,PR 8例,总缓解率55%;主要毒副反应为骨髓抑制和胃肠道反应,多为Ⅰ～Ⅱ级.其它毒副反应少见.结论:HCPT和5-Fu联合化疗晚期胃肠道肿瘤的疗效肯定,毒副作用可以耐受,价格低廉,值得临床推广.

白血病是一种以全身性造血系统呈现白细胞异常增生性疾病,占青少年恶性肿瘤发病的首位这[1],如何提高缓解率乃是关键问题.近3年来我们采用HAC方案治疗成人急性非淋巴细胞白血病(ANLL)20例,现报告如下: